Snia shareholders in pact against Biosdue merger
This article was originally published in Clinica
Executive Summary
Six institutional shareholders of Italian biomedical and chemicals group Snia have formed a pact aimed at blocking the merger with Italian financial company Biosdue. The shareholders, representing 12.6% of the capital, are concerned that Biosdue sees the merger as a means of reducing its debt levels, the latter being secured by disposal of assets of the merged entity.